In the BioHarmony Drug Report Database
Drospirenone
Slynd, Drovelis, Lydisilka (drospirenone) is a small molecule pharmaceutical. Drospirenone was first approved as Slynd on 2019-05-23. It has been approved in Europe to treat contraception. The pharmaceutical is active against mineralocorticoid receptor. Yasmin’s patent is valid until 2031-06-28 (FDA).
Trade Name
|
Drovelis, Lydisilka |
|---|---|
Common Name
|
drospirenone |
ChEMBL ID
|
CHEMBL1509 |
Indication
|
contraception |
Drug Class
|
Aldosterone antagonists (spironolactone type) |
Image (chem structure or protein)